Neumora Therapeutics (NMRA) EBT (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly EBT came in at -$53.4 million in Q1 2026, up 21.3% year-on-year from -$44.0 million in Q1 2025, and up 10.13% quarter-over-quarter from -$59.5 million in Q4 2025.
Neumora Therapeutics (NMRA) EBT (2022 - 2026) Analysis & Trends
Neumora Therapeutics' EBT history runs 5 years deep, the most recent figure standing at -$53.4 million for Q1 2026.
- On a quarterly basis, EBT rose 21.3% year-over-year to -$53.4 million in Q1 2026; TTM through Mar 2026 was -$222.3 million, a 13.74% increase from a year earlier, with the FY2025 full-year figure at -$236.8 million, up 2.79% from the prior year.
- EBT rose to -$53.4 million in Q1 2026 per NMRA's latest filing, from -$59.5 million in the prior quarter.
- Across five years, EBT topped out at -$30.9 million in Q3 2022 and bottomed at -$171.9 million in Q4 2022.
- The 5-year median for EBT is -$56.8 million (2025), against an average of -$65.0 million.
- Across the five-year window, EBT plunged 71.69% in 2023 and jumped 45.78% in 2024, its largest moves.
- Year by year, EBT stood at -$171.9 million in 2022, then jumped by 36.9% to -$108.5 million in 2023, then surged by 45.78% to -$58.8 million in 2024, then dropped by 1.09% to -$59.5 million in 2025, then advanced by 10.13% to -$53.4 million in 2026.
- Per Business Quant, the three latest NMRA EBT figures stand at -$53.4 million (Q1 2026), -$59.5 million (Q4 2025), and -$56.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - | -53.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.43 Mn |
| Dec 31, 2025 | -59.45 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.71 Mn |
| Mar 31, 2025 | -67.89 Mn |
| Dec 31, 2024 | -58.81 Mn |
| Sep 30, 2024 | -72.49 Mn |
| Jun 30, 2024 | -58.58 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -38.69 Mn |
| Dec 31, 2022 | -171.90 Mn |
| Sep 30, 2022 | -30.89 Mn |